Table 1

Demographic and clinical characteristics of study population

HBeAg positive
(n=163)
HBeAg negative
(n=150)
Z*2 P value
Gender (male:female)99:6491:590.011†0.9178
Age (years; M, IQR)31 (28–37)42 (35–50)8.600<0.0001
ALT (U/L; M, IQR)69 (42–156.75)35.5 (18–107)4.115<0.0001
Serum HBsAg (log10 IU/mL; M, IQR)4.117 (3.691–4.635)3.296 (2.745–3.702)10.417<0.0001
Serum anti-HBc (log10 IU/mL; M, IQR)3.526 (3.211–3.819)4.225 (3.680–4.642)8.520<0.0001
Serum HBcrAg (log10 IU/mL; M, IQR)8.200 (7.700–8.500)4.1500 (3.000–5.800)13.779<0.0001
Serum HBV DNA (log10 IU/mL; M, IQR)7.314 (6.469–7.903)3.588 (2.699–5.681)12.668<0.0001
HBsAg IHC (0:1:2:3)3:36:59:6510:65:52:2332.098†<0.0001
HBcAg IHC (0:1:2:3)58:47:48:10121:26:3:077.514†<0.0001
HBV DNA-ISH positive area (%; M, IQR)7.949 (4.365–15.733)1.556 (0.687–3.685)10.030<0.0001
HBV DNA-ISH score (0:1:2:3:4)2:14:33:52:6113:50:57:24:689.853†<0.0001
Grade (1:2:3:4)95:57:11:0115:21:14:018.372†0.0001
Stage (1:2:3:4)71:60:11:2190:30:9:2111.923†0.0077
  • *Mann-Whitney U test.

  • †Pearson χ2 test.

  • HBcrAg, HBV core related antigen; ISH, in situ hybridisation; M, median.